Article
ST3Gal1 synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer
medRxiv · 2023 · Garnham, R.; Geh, D.; Nelson, R.; Ramon-Gil, E.; Wilson, L.; Schmidt, E. N.; Walker, L.; Adamson, B.; Buskin, A.; Hepburn, A.; Hodgson, K.; Kendall, H.; Frame, F. M.; Maitland, N. J.; Coffey, K.; Robson, C. N.; Elliott, D. J.; Heer, R.; Macauley, M. S.; Munkley, J.; Gaughan, L.; Leslie, J.; Scott, E.
Key facts
| Title | ST3Gal1 synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer |
|---|---|
| First author | Garnham, R.; Geh, D.; Nelson, R.; Ramon-Gil, E.; Wilson, L.; Schmidt, E. N.; Walker, L.; Adamson, B.; Buskin, A.; Hepburn, A.; Hodgson, K.; Kendall, H.; Frame, F. M.; Maitland, N. J.; Coffey, K.; Robson, C. N.; Elliott, D. J.; Heer, R.; Macauley, M. S.; Munkley, J.; Gaughan, L.; Leslie, J.; Scott, E. |
| Journal | medRxiv |
| Published | Apr 4, 2023 |
| DOI | 10.1101/2023.04.03.535346 |
| Product codes mentioned | MVU |
At a glance
- None FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1